Cell Therapy Bioprocessing
- Type: Archived Webinar
- Level: Intermediate
- Duration: 1 hour
- PDHs: 1.00
As cellular therapies are advancing through clinical development and getting closer to market, close collaborations between stem cell biologists, clinical cell processing technologists, and bioengineers will be required for effective commercialization of this new class of drugs. New cell production strategies and technologies will be needed to supply sufficient quantities of cells, of pre-defined quality and biological functionality, and at reasonable costs as these new products come to market. Just as protein therapeutics went through a technology transformation during the 1990’s, cell therapy bioprocessing technologies will go through a similar standardization and scalability evolution over the next 5-15 years. This Webinar will outline many of the challenges and opportunities that lie before the Cell Therapy industry as it transforms from a niche market industry to blockbuster drug status, with a real-world example of a cell therapy drug in mid-stage clinical development.
Please join us as this new industry evolves, and as the technical discipline of Cell Therapy Bioprocesing is emerging.
Dr. Peter Zandstra graduated with a Bachelor of Engineering degree from McGill University in the Department of Chemical Engineering, and obtained his Ph.D. degree from the University of British Columbia (UBC) in the Department of Chemical Engineering and Biotechnology, under the supervision of Jamie Piret and Connie Eaves. He continued his research training as a Post-Doctoral Fellow in the field of Bioengineering at the Massachusetts Institute of Technology (with Doug Lauffenburger). In 1999, Dr. Zandstra began his faculty appointment at the University of Toronto’s (UofT’s) Institute...Read more
|AIChE Graduate Student Members||Free|
|AIChE Undergraduate Student Members||Free|